Angèle Maki
About Angèle Maki
Angèle Maki serves as the Chief Business Officer at Hummingbird Bioscience, where she focuses on strategic growth and external collaborations. With over 20 years of experience in the biotech and pharma industry, she has held various leadership roles and has a strong background in molecular biology and business development.
Current Role at Hummingbird Bioscience
Angèle Maki serves as the Chief Business Officer at Hummingbird Bioscience, a position she has held since 2023. In this role, she steers strategic growth, external collaborations, and investor relations. Her focus is on engineering precision biotherapeutics, leveraging her extensive background in the biotech and pharmaceutical sectors.
Experience at Eli Lilly and Company
From 2019 to 2021, Angèle Maki worked at Eli Lilly and Company as Vice President of Venture Science within Corporate Business Development. This role took place in South San Francisco and involved sourcing and executing partnerships across various therapeutic areas and platforms.
Educational Background
Angèle Maki has a strong academic foundation in the life sciences. She completed her PhD in Biological Chemistry at Stanford University. Prior to that, she earned a Postdoctoral degree from Scripps Research in Molecular Biology. Her undergraduate studies culminated in a Bachelor of Science in Chemistry from The University of Winnipeg.
Advisory Roles and Board Memberships
In addition to her role at Hummingbird Bioscience, Angèle Maki is currently an Advisor at Paradox Immunotherapeutics and Pear VC, both positions she has held since 2021 and 2023 respectively. She also serves on the Leadership Team as a Director and Board Member at CELS - Canadian Entrepreneurs in Life Science since 2023.
Career History in Biotech and Pharma
Angèle Maki has accumulated 20 years of experience in the biotech and pharmaceutical industry. Her previous roles include Senior Vice President and Head of Business Development at ReCode Therapeutics, Executive Director of Business Development & Licensing at Merck, and Associate Director of Business Development at Genentech. She has a proven track record in business development leadership, combining scientific expertise with strategic initiatives.